Introducing the Next Generation Drug Discovery Platforms

Newormics is a developer of the first high-throughput, high-content in vivo drug screening platforms for use with small animal models. The company provides novel optical and micro-technologies to advance early stage drug discovery for faster, better drug development with cost-effective solutions. The company is co-founded by Prof. Adela Ben-Yakar, Dr. Sudip Mondal, and Evan Hegarty from the Mechanical Engineering Department at the University of Texas at Austin.